Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole

Yoshinao Muro, Kazumitsu Sugiura, Yukiko Nitta, Teruyuki Mitsuma, Kei Hoshino, Toshikazu Usuda, Kaori Hayashi, Yumi Murase, Makoto Shimizu, Hiromi Matsuo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective. The high frequency of gastroesophageal reflux disease (GERD) as a complication of scleroderma (systemic sclerosis, SSc) calls for treatment with powerful acid suppressants such as proton pump inhibitors (PPI). The present study used a GERD-specific questionnaire to assess the symptoms of GERD in SSc patients, and examine the effectiveness of rabeprazole (RPZ) for treating the symptoms of GERD. Methods. The Frequency Scale for the Symptoms of GERD (FSSG), a medical questionnaire developed in Japan for evaluating GERD, and the Visual Analogue Scale (VAS) were used to evaluate GERD symptoms and the degree of pain, respectively, in 151 SSc subjects. These tools were also used to assess the effect of 8 weeks' treatment with the PPI RPZ (10 mg/day). Results. Data on age and gender, and FSSG and VAS scores before treatment and after 4 and 8 weeks' RPZ treatment, were available for 84 subjects. The mean FSSG score was 13.9±9.7 before treatment, 8.3±8.1 after 4 weeks of treatment, and 7.0±7.0 after 8 weeks of treatment; the score reduction was significant (p<0.001) indicating the effectiveness of RPZ in improving subjective GERD symptoms. The VAS scores revealed a significant improvement in pain after both 4 and 8 weeks compared with baseline scores. Six subjects experienced adverse effects and five discontinued the analysis during the period. Conclusion. Administration of RPZ 10 mg/day is effective for the control of the symptoms of GERD associated with SSc. In addition to assessing the symptoms of GERD, the FSSG questionnaire can be used to evaluate the therapeutic effect of drugs.

Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume27
Issue number3 SUPPL. 54
Publication statusPublished - 29-10-2009
Externally publishedYes

Fingerprint

Rabeprazole
Gastroesophageal Reflux
Systemic Scleroderma
Visual Analog Scale
Proton Pump Inhibitors
Therapeutics
Pain
Therapeutic Uses

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Muro, Y., Sugiura, K., Nitta, Y., Mitsuma, T., Hoshino, K., Usuda, T., ... Matsuo, H. (2009). Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole. Clinical and Experimental Rheumatology, 27(3 SUPPL. 54).
Muro, Yoshinao ; Sugiura, Kazumitsu ; Nitta, Yukiko ; Mitsuma, Teruyuki ; Hoshino, Kei ; Usuda, Toshikazu ; Hayashi, Kaori ; Murase, Yumi ; Shimizu, Makoto ; Matsuo, Hiromi. / Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole. In: Clinical and Experimental Rheumatology. 2009 ; Vol. 27, No. 3 SUPPL. 54.
@article{97aefa3a6ba84507b7b2926f88895cdb,
title = "Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole",
abstract = "Objective. The high frequency of gastroesophageal reflux disease (GERD) as a complication of scleroderma (systemic sclerosis, SSc) calls for treatment with powerful acid suppressants such as proton pump inhibitors (PPI). The present study used a GERD-specific questionnaire to assess the symptoms of GERD in SSc patients, and examine the effectiveness of rabeprazole (RPZ) for treating the symptoms of GERD. Methods. The Frequency Scale for the Symptoms of GERD (FSSG), a medical questionnaire developed in Japan for evaluating GERD, and the Visual Analogue Scale (VAS) were used to evaluate GERD symptoms and the degree of pain, respectively, in 151 SSc subjects. These tools were also used to assess the effect of 8 weeks' treatment with the PPI RPZ (10 mg/day). Results. Data on age and gender, and FSSG and VAS scores before treatment and after 4 and 8 weeks' RPZ treatment, were available for 84 subjects. The mean FSSG score was 13.9±9.7 before treatment, 8.3±8.1 after 4 weeks of treatment, and 7.0±7.0 after 8 weeks of treatment; the score reduction was significant (p<0.001) indicating the effectiveness of RPZ in improving subjective GERD symptoms. The VAS scores revealed a significant improvement in pain after both 4 and 8 weeks compared with baseline scores. Six subjects experienced adverse effects and five discontinued the analysis during the period. Conclusion. Administration of RPZ 10 mg/day is effective for the control of the symptoms of GERD associated with SSc. In addition to assessing the symptoms of GERD, the FSSG questionnaire can be used to evaluate the therapeutic effect of drugs.",
author = "Yoshinao Muro and Kazumitsu Sugiura and Yukiko Nitta and Teruyuki Mitsuma and Kei Hoshino and Toshikazu Usuda and Kaori Hayashi and Yumi Murase and Makoto Shimizu and Hiromi Matsuo",
year = "2009",
month = "10",
day = "29",
language = "English",
volume = "27",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "3 SUPPL. 54",

}

Muro, Y, Sugiura, K, Nitta, Y, Mitsuma, T, Hoshino, K, Usuda, T, Hayashi, K, Murase, Y, Shimizu, M & Matsuo, H 2009, 'Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole', Clinical and Experimental Rheumatology, vol. 27, no. 3 SUPPL. 54.

Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole. / Muro, Yoshinao; Sugiura, Kazumitsu; Nitta, Yukiko; Mitsuma, Teruyuki; Hoshino, Kei; Usuda, Toshikazu; Hayashi, Kaori; Murase, Yumi; Shimizu, Makoto; Matsuo, Hiromi.

In: Clinical and Experimental Rheumatology, Vol. 27, No. 3 SUPPL. 54, 29.10.2009.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole

AU - Muro, Yoshinao

AU - Sugiura, Kazumitsu

AU - Nitta, Yukiko

AU - Mitsuma, Teruyuki

AU - Hoshino, Kei

AU - Usuda, Toshikazu

AU - Hayashi, Kaori

AU - Murase, Yumi

AU - Shimizu, Makoto

AU - Matsuo, Hiromi

PY - 2009/10/29

Y1 - 2009/10/29

N2 - Objective. The high frequency of gastroesophageal reflux disease (GERD) as a complication of scleroderma (systemic sclerosis, SSc) calls for treatment with powerful acid suppressants such as proton pump inhibitors (PPI). The present study used a GERD-specific questionnaire to assess the symptoms of GERD in SSc patients, and examine the effectiveness of rabeprazole (RPZ) for treating the symptoms of GERD. Methods. The Frequency Scale for the Symptoms of GERD (FSSG), a medical questionnaire developed in Japan for evaluating GERD, and the Visual Analogue Scale (VAS) were used to evaluate GERD symptoms and the degree of pain, respectively, in 151 SSc subjects. These tools were also used to assess the effect of 8 weeks' treatment with the PPI RPZ (10 mg/day). Results. Data on age and gender, and FSSG and VAS scores before treatment and after 4 and 8 weeks' RPZ treatment, were available for 84 subjects. The mean FSSG score was 13.9±9.7 before treatment, 8.3±8.1 after 4 weeks of treatment, and 7.0±7.0 after 8 weeks of treatment; the score reduction was significant (p<0.001) indicating the effectiveness of RPZ in improving subjective GERD symptoms. The VAS scores revealed a significant improvement in pain after both 4 and 8 weeks compared with baseline scores. Six subjects experienced adverse effects and five discontinued the analysis during the period. Conclusion. Administration of RPZ 10 mg/day is effective for the control of the symptoms of GERD associated with SSc. In addition to assessing the symptoms of GERD, the FSSG questionnaire can be used to evaluate the therapeutic effect of drugs.

AB - Objective. The high frequency of gastroesophageal reflux disease (GERD) as a complication of scleroderma (systemic sclerosis, SSc) calls for treatment with powerful acid suppressants such as proton pump inhibitors (PPI). The present study used a GERD-specific questionnaire to assess the symptoms of GERD in SSc patients, and examine the effectiveness of rabeprazole (RPZ) for treating the symptoms of GERD. Methods. The Frequency Scale for the Symptoms of GERD (FSSG), a medical questionnaire developed in Japan for evaluating GERD, and the Visual Analogue Scale (VAS) were used to evaluate GERD symptoms and the degree of pain, respectively, in 151 SSc subjects. These tools were also used to assess the effect of 8 weeks' treatment with the PPI RPZ (10 mg/day). Results. Data on age and gender, and FSSG and VAS scores before treatment and after 4 and 8 weeks' RPZ treatment, were available for 84 subjects. The mean FSSG score was 13.9±9.7 before treatment, 8.3±8.1 after 4 weeks of treatment, and 7.0±7.0 after 8 weeks of treatment; the score reduction was significant (p<0.001) indicating the effectiveness of RPZ in improving subjective GERD symptoms. The VAS scores revealed a significant improvement in pain after both 4 and 8 weeks compared with baseline scores. Six subjects experienced adverse effects and five discontinued the analysis during the period. Conclusion. Administration of RPZ 10 mg/day is effective for the control of the symptoms of GERD associated with SSc. In addition to assessing the symptoms of GERD, the FSSG questionnaire can be used to evaluate the therapeutic effect of drugs.

UR - http://www.scopus.com/inward/record.url?scp=70350330501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350330501&partnerID=8YFLogxK

M3 - Article

VL - 27

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 3 SUPPL. 54

ER -